BusinessPeregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other CancersBy Nasdaq OMXJan 11, 2016, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With BavituximabBy Nasdaq OMXJan 6, 2016, 1:05 PM UTC
BusinessOncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without Brain Metastases at the San Antonio Breast Cancer SymposiumBy Nasdaq OMXDec 8, 2015, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXDec 7, 2015, 9:05 PM UTC
BusinessPeregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015By Nasdaq OMXDec 3, 2015, 9:05 PM UTC
BusinessOncothyreon Announces Webcast to Review Updated Clinical Data on ONT-380 in HER2-Positive Breast Cancer PatientsBy Nasdaq OMXDec 2, 2015, 1:00 PM UTC
